This site is intended for U.S. Healthcare Professionals.

ONUREG® is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

Request a Rep

Explore the video library to learn more about ONUREG® (oral azacitidine) and its pivotal trial in acute myeloid leukemia

Clinical Conversations with Thomas LeBlanc, MD
and James McCloskey, MD

Looking for an overview? Listen to experts discuss
the pivotal QUAZAR® AML-001 trial

Choosing a Treatment Path for Your Patients
in First AML Remission

Looking to dive deeper? Gain insights about treatment
from James McCloskey, MD